Dive into the archives.
- Biogen Reports 13th Case of PML
By KEITH J. WINSTEIN
Biogen Idec Inc.’s disclosure of a debilitating brain infection in a patient taking its Tysabri multiple-sclerosis medicine sparked a selloff in shares of the biotechnology company Monday.
The disclosure, made Friday evening, marks the 13th case of the infection, called progressive multifocal leukoencephalopathy or PML, in a Tysabri patient. Three of the patients [...]
- Hot off the ENS Press…Rebif Autoinject Improves SC Delivery
MILAN, Italy
June 26, 2009
A new electronic, multidose, autoinjection device improves subcutaneous delivery of interferon beta (IFNB)-1a in patients with relapsing multiple sclerosis (MS), according to a study presented here at the 19th Meeting of the European Neurological Society (ENS2009).
Virginia Devonshire, MD, Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, presented [...]
- 10th PML Case Confirmed by Biogen
Biogen Idec Inc. has reported a new case of a potentially lethal brain inflammation in a patient using its drug Tysabri, the tenth such case since the drug was reintroduced three years ago.
The company said late Friday it confirmed the presence of progressive multifocal leukoencephalopathy, or PML, on Tuesday. Biogen said the patient, who lives [...]
- Teva completes enrollment in second Phase III trial
Jun 26, 2009 (Datamonitor via COMTEX) — Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and Active Biotech, a Swedish pharmaceutical company, have completed patient enrollment for the second pivotal Phase III clinical trial, Bravo, evaluating the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis.
// Bravo is a global clinical [...]
- Hot off the ENS Press: Immunomodulatory Treatment Improves Cognitive Function in PWMS
By Judith Moser, MD
MILAN, Italy — June 26, 2009 — Patients with relapsing-remitting multiple sclerosis (RRMS) who receive glatiramer acetate (GA) or interferon (IFN) beta show a reduction in cognitive impairment and relative stability of cognitive and affective variables at 2 years, according to the results of an observational study presented here at the 19th [...]
- Put on Your Thinking Cap: Learning Increases Myelin
Researchers at Oxford have proven that, when people learn a new skill (juggling), brain imaging shows that the white matter in their brain increased. This increase in white matter is most likely due to myelination. In other words, the brain is capable of increase myelin in response to learning even into adulthood. This is good [...]
- Riddler: Who Will Benefit Most From A New MS Therapy?
In a recent phase II clinical trial, the drug alemtuzumab (Campath-1H) was found to be a highly effective treatment for individuals with early relapsing-remitting multiple sclerosis. However, a substantial proportion of the patients treated (30%) went on to develop another autoimmune disease, mostly thyroid autoimmunity. Now, Joanne Jones and colleagues, at the University of Cambridge, [...]
- Hot off the ENS Press: Cladribine Is Safe Overall in Patients With Multiple Sclerosis
MILAN, Italy — June 24, 2009 — According to a safety analysis of a study presented here at the 19th Meeting of the European Neurological Society (ENS), the incidence of treatment-emergent adverse events in the trial was comparable between 2 doses of cladribine and placebo in patients with multiple sclerosis (MS), with exceptions related to [...]
- Tysabri Side Effects Linked to 9th PML Infection Case
A new case of a rare, often lethal, brain infection has been linked to the multiple sclerosis drug Tysabri, making it the ninth case of progressive multifocal leukoencephalopathy (PML) infection potentially caused by side effects of Tysabri since the drug was put back on the market in July 2006.
Biogen Idec Inc., the maker of Tysabri, [...]
- Biogen enrolls patients in new MS trial
Biogen Idec has enrolled its first patient in a phase 3 trial for a potential multiple sclerosis treatment that, when compared with existing therapies, would reduce the number of injections patients must receive.
The trial, called ADVANCE, will determine the efficacy and safety of Biogen’s drug target, called PEGylated interferon beta-1a, in reducing relapse rates in [...]
